Elevance Health (NYSE:ELV) Releases Earnings Results, Beats Estimates By $1.27 EPS

Elevance Health (NYSE:ELV) released its earnings results on Wednesday. The company reported $7.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.18 by $1.27, Briefing.com reports. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.83 billion during the quarter, compared to analyst estimates of $48.84 billion. During the same period in the prior year, the company posted $8.84 earnings per share. Elevance Health’s quarterly revenue was up .8% on a year-over-year basis.

Elevance Health Stock Up 1.2%

ELV opened at $430.21 on Wednesday. Elevance Health has a 12 month low of $273.71 and a 12 month high of $436.24. The company has a market cap of $93.42 billion, a PE ratio of 18.30, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The company has a 50 day moving average of $399.37 and a 200 day moving average of $354.74.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Investors of record on Wednesday, June 10th were issued a $1.72 dividend. The ex-dividend date of this dividend was Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.6%. Elevance Health’s dividend payout ratio (DPR) is 29.26%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Robert W. Baird boosted their price target on shares of Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a report on Thursday, April 23rd. Morgan Stanley lifted their price objective on shares of Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a research report on Thursday, June 4th. Barclays boosted their target price on shares of Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. Evercore reissued a “hold” rating on shares of Elevance Health in a research report on Tuesday, May 19th. Finally, The Goldman Sachs Group raised their price target on shares of Elevance Health from $350.00 to $370.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Fifteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $435.05.

Insider Activity

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the transaction, the director directly owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.34% of the stock is currently owned by corporate insiders.

Institutional Trading of Elevance Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Caden Capital Partners LP purchased a new position in Elevance Health in the 4th quarter worth approximately $101,000. Miller Capital Partners Inc. purchased a new stake in Elevance Health during the fourth quarter valued at about $159,000. Ankerstar Wealth LLC purchased a new stake in Elevance Health during the fourth quarter valued at about $112,000. HM Payson & Co. lifted its stake in Elevance Health by 15.0% during the fourth quarter. HM Payson & Co. now owns 437 shares of the company’s stock worth $153,000 after purchasing an additional 57 shares during the last quarter. Finally, Sepio Capital LP purchased a new position in shares of Elevance Health in the 4th quarter worth about $201,000. 89.24% of the stock is currently owned by institutional investors.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Elevance reported Q2 results ahead of expectations, with management saying performance improved across its diversified portfolio and that it is raising 2026 adjusted EPS guidance to at least $27.00. Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: Medical cost management appears to be improving, with lower medical costs in some plans helping lift profits and supporting a better outlook for the rest of the year. Elevance raises annual profit forecast on better medical cost management
• Positive Sentiment: The company also benefited from higher sales in the quarter, which helped offset pressure from a higher benefit-expense ratio. Elevance Health Raises Earnings Outlook on Higher Sales
• Positive Sentiment: Truist raised its price target on ELV to $475 and reiterated a buy rating, signaling increased analyst confidence after the earnings update. Elevance Health (NYSE:ELV) Price Target Raised to $475.00 at Truist Financial
• Neutral Sentiment: Pre-earnings commentary had flagged possible pressure from weaker Health Benefits results and higher benefit expenses, but those concerns were at least partly offset by the reported quarter. Will Health Benefits Weakness Drag Elevance’s Q2 Earnings?

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.